HNSCC
MCID: SQM013
MIFTS: 82

Squamous Cell Carcinoma, Head and Neck (HNSCC)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Squamous Cell Carcinoma, Head and Neck

MalaCards integrated aliases for Squamous Cell Carcinoma, Head and Neck:

Name: Squamous Cell Carcinoma, Head and Neck 57 13
Squamous Cell Carcinoma of the Head and Neck 38 12 53 25 75 29 6 15 73
Hnscc 57 53 25 75 55
Head and Neck Squamous Cell Carcinoma 12 53 25 15
Carcinoma, Squamous Cell of Head and Neck 76 53 44
Head and Neck Cancer 53 43
Squamous Cell Carcinoma of the Nasal Cavity and Paranasal Sinuses 59
Squamous Cell Carcinoma of the Nasal Cavity and Sinuses 59
Squamous Cell Carcinoma, Head and Neck, Somatic 57
Squamous Cell Carcinoma of the Hypopharynx 59
Squamous Cell Carcinoma of Salivary Glands 59
Squamous Cell Carcinoma of the Oral Cavity 59
Squamous Cell Carcinomas of Head and Neck 12
Squamous Cell Carcinoma of the Oropharynx 59
Carcinoma, Squamous Cell, Head and Neck 40
Squamous Cell Carcinoma of the Larynx 59
Squamous Cell Carcinoma of the Lip 59
Carcinoma of the Head and Neck 12
Squamous Cell Carcinoma of Lip 73
Lip Squamous Cell Carcinoma 55
Neoplasm of Head and Neck 6
Cancer of Head and Neck 73
Cancer, Head/neck 40
Scchn 25

Characteristics:

OMIM:

57
Inheritance:
autosomal recessive


HPO:

32
squamous cell carcinoma, head and neck:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Squamous Cell Carcinoma, Head and Neck

MedlinePlus : 43 Head and neck cancer includes cancers of the mouth, nose, sinuses, salivary glands, throat, and lymph nodes in the neck. Most begin in the moist tissues that line the mouth, nose, and throat. Symptoms include A lump or sore that does not heal A sore throat that does not go away Trouble swallowing A change or hoarseness in the voice Head and neck cancers are twice as common in men. Using tobacco or alcohol increases your risk. In fact, around 75 percent of head and neck cancers are linked to tobacco use, including smoking and smokeless tobacco. Infection with HPV is a risk factor for some head and neck cancers. To diagnose head and neck cancer, your doctor will do a physical exam and diagnostic tests. You will have a biopsy, where a sample of tissue is taken out and examined under a microscope. It is the only test that can tell for sure if you have cancer. If found early, these cancers are often curable. Treatments may include surgery, radiation therapy, chemotherapy, or a combination. Treatments can affect eating, speaking or even breathing, so patients may need rehabilitation. NIH: National Cancer Institute

MalaCards based summary : Squamous Cell Carcinoma, Head and Neck, also known as squamous cell carcinoma of the head and neck, is related to tongue squamous cell carcinoma and squamous cell carcinoma, and has symptoms including tinnitus, snoring and coughing. An important gene associated with Squamous Cell Carcinoma, Head and Neck is ING1 (Inhibitor Of Growth Family Member 1), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Erbitux and Ethyol have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and lymph node, and related phenotypes are squamous cell carcinoma and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A head and neck carcinoma that has material basis in squamous cells that line the moist, mucosal surfaces inside the head and neck.

Genetics Home Reference : 25 Squamous cell carcinoma is a cancer that arises from particular cells called squamous cells. Squamous cells are found in the outer layer of skin and in the mucous membranes, which are the moist tissues that line body cavities such as the airways and intestines. Head and neck squamous cell carcinoma (HNSCC) develops in the mucous membranes of the mouth, nose, and throat.

NIH Rare Diseases : 53 Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck (for example, inside the mouth, the nose, and the throat). These squamous cell cancers are often referred to as squamous cell carcinomas of the head and neck. At least 75 % of head and neck cancers are caused by tobacco and alcohol use. Infection with cancer-causing types of human papillomavirus (HPV), especially HPV-16, is a risk factor for some types of head and neck cancers. The symptoms of head and neck cancers may include a lump or a sore that does not heal, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice. Treatment for head and neck cancer can include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of treatments.

UniProtKB/Swiss-Prot : 75 Squamous cell carcinoma of the head and neck: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes.

Wikipedia : 76 Squamous cell carcinomas (SCCs), also known as epidermoid carcinoma, comprise a number of different... more...

Description from OMIM: 275355

Related Diseases for Squamous Cell Carcinoma, Head and Neck

Diseases related to Squamous Cell Carcinoma, Head and Neck via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 366)
# Related Disease Score Top Affiliating Genes
1 tongue squamous cell carcinoma 32.5 AKT1 MIR21 TP53
2 squamous cell carcinoma 31.5 AKT1 BRAF FGFR3 H19 HRAS ING1
3 melanoma 31.2 BRAF H19 MIR205 MIR210 PTEN TP53
4 colorectal cancer 31.1 AKT1 BRAF FGFR3 GNAS H19 HRAS
5 actinic cheilitis 31.1 FGFR3 TP53
6 lung squamous cell carcinoma 31.0 AKT1 BRAF FGFR3 HRAS NFE2L2 PIK3CA
7 cervical cancer 30.9 AKT1 FGFR3 GNAS H19 HRAS MIR21
8 adenocarcinoma 30.9 AKT1 BRAF FGFR3 GNAS H19 HRAS
9 esophageal cancer 30.9 AKT1 H19 HRAS MIR205 MIR21 PIK3CA
10 suppression of tumorigenicity 12 30.9 AKT1 BRAF HRAS PIK3CA PTEN SMAD4
11 small cell cancer of the lung 30.8 AKT1 MIR21 PIK3CA PTEN TP53
12 lung cancer 30.8 AKT1 BRAF FGFR3 H19 HRAS MIR205
13 prostate cancer 30.8 AKT1 H19 HRAS MIR205 MIR21 MIR210
14 adenoid cystic carcinoma 30.8 AKT1 HRAS PIK3CA PTEN TP53
15 thyroid cancer 30.8 AKT1 BRAF GNAS H19 HRAS PIK3CA
16 glioma 30.8 BRAF H19 IDH2 MIR21 MIR210 PIK3CA
17 breast adenocarcinoma 30.8 AKT1 H19 PIK3CA PTEN SMAD4 TP53
18 nasopharyngeal carcinoma 30.8 AKT1 H19 HRAS PIK3CA TP53
19 adamantinoma of long bones 30.8 BRAF H19 PIK3CA PTEN TNFRSF10B TP53
20 bladder cancer 30.8 FGFR3 H19 HRAS MIR205 MIR21 TP53
21 leukemia, chronic lymphocytic 2 30.7 BRAF HRAS TP53
22 adenoma 30.7 BRAF GNAS SMAD4 TP53
23 differentiated thyroid carcinoma 30.7 BRAF HRAS TP53
24 pancreatic cancer 30.5 AKT1 H19 HRAS MIR205 MIR21 MIR210
25 ovarian cancer 30.5 AKT1 BRAF H19 MIR21 MIR210 PIK3CA
26 gastric cancer 30.5 AKT1 H19 MIR21 PIK3CA PTEN SMAD4
27 oral cavity cancer 30.5 PIK3CA PTEN TNFRSF10B TP53
28 ovary adenocarcinoma 30.4 HRAS PIK3CA TP53
29 larynx cancer 30.3 MIR21 PTEN TP53
30 cheilitis glandularis 11.5
31 tongue cancer 11.3
32 salivary gland carcinoma 11.3
33 oral cancer 11.3
34 salivary gland cancer, adult 11.0
35 basaloid squamous cell carcinoma 10.6
36 breast cancer 10.6 AKT1 BRAF GNAS H19 HRAS ING1
37 hepatocellular carcinoma 10.6 AKT1 GNAS H19 HRAS IDH2 MIR205
38 large intestine cancer 10.6 AKT1 BRAF GNAS HRAS IDH2 PIK3CA
39 merkel cell carcinoma 10.6
40 gastric adenocarcinoma 10.6 AKT1 BRAF GNAS H19 HRAS MAP2K2
41 lung cancer susceptibility 3 10.6 AKT1 BRAF FGFR3 GNAS H19 HRAS
42 cholangiocarcinoma 10.6 AKT1 BRAF H19 IDH2 MIR21 PIK3CA
43 glioblastoma 10.5 AKT1 BRAF H19 HRAS IDH2 MIR21
44 renal cell carcinoma, papillary, 1 10.5 BRAF FGFR3 HRAS NFE2L2 PIK3CA PTEN
45 pancreas adenocarcinoma 10.5 AKT1 GNAS HRAS MAP2K2 PIK3CA SMAD4
46 bladder urothelial carcinoma 10.5 AKT1 BRAF FGFR3 HRAS NFE2L2 PIK3CA
47 brain cancer 10.5 AKT1 BRAF HRAS IDH2 PIK3CA PTEN
48 endocrine gland cancer 10.5 AKT1 GNAS HRAS PTEN SMAD4 TP53
49 gastrointestinal system cancer 10.5 AKT1 H19 HRAS PIK3CA PTEN TP53
50 myeloma, multiple 10.5 AKT1 BRAF FGFR3 H19 HRAS IDH2

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma, Head and Neck:



Diseases related to Squamous Cell Carcinoma, Head and Neck

Symptoms & Phenotypes for Squamous Cell Carcinoma, Head and Neck

Symptoms via clinical synopsis from OMIM:

57
Lab:
beta family transforming growth factor resistance


Clinical features from OMIM:

275355

Human phenotypes related to Squamous Cell Carcinoma, Head and Neck:

32
# Description HPO Frequency HPO Source Accession
1 squamous cell carcinoma 32 HP:0002860

UMLS symptoms related to Squamous Cell Carcinoma, Head and Neck:


tinnitus, snoring, coughing, sore throat, vertigo/dizziness, equilibration disorder, halitosis

GenomeRNAi Phenotypes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

26 (show all 35)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.27 SMAD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.27 SMAD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.27 PTEN
4 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.27 PTEN
5 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.27 PIK3CA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.27 AKT1 IDH2 PIK3CA PTEN
7 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.27 PIK3CA
8 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.27 PTEN
9 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.27 IDH2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.27 AKT1 IDH2 PIK3CA
11 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.27 PIK3CA
12 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.27 SMAD4
13 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.27 IDH2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.27 SMAD4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.27 PTEN
16 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.27 SMAD4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.27 AKT1 IDH2 PIK3CA PTEN SMAD4
18 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.27 SMAD4
19 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.27 SMAD4
20 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.27 PIK3CA
21 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.27 AKT1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.27 SMAD4
23 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.27 PTEN
24 Increased shRNA abundance (Z-score > 2) GR00366-A-69 10.27 IDH2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.27 AKT1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.27 IDH2 SMAD4
27 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.27 SMAD4
28 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.27 AKT1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.27 SMAD4
30 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.27 AKT1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.27 PTEN
32 Decreased viability in esophageal squamous lineage GR00235-A 9.9 BRAF FGFR3 GNAS HRAS IDH2 ING1
33 Decreased cell migration GR00055-A-1 9.8 AKT1 BRAF FGFR3 HRAS MAP2K2 PIK3CA
34 Decreased sensitivity to paclitaxel GR00112-A-0 9.26 PTEN SMAD4
35 Reduced mammosphere formation GR00396-S 9.23 BRAF GNAS H19 HRAS IDH2 NFE2L2

MGI Mouse Phenotypes related to Squamous Cell Carcinoma, Head and Neck:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 AKT1 BRAF FGFR3 GNAS HRAS ING1
2 cardiovascular system MP:0005385 10.28 AKT1 BRAF GNAS HRAS IDH2 MAP2K2
3 cellular MP:0005384 10.26 AKT1 BRAF FGFR3 GNAS ING1 MAP2K2
4 growth/size/body region MP:0005378 10.23 AKT1 BRAF FGFR3 GNAS HRAS ING1
5 homeostasis/metabolism MP:0005376 10.21 AKT1 BRAF FGFR3 GNAS HRAS ING1
6 endocrine/exocrine gland MP:0005379 10.18 AKT1 BRAF GNAS HRAS ING1 MAP2K2
7 adipose tissue MP:0005375 10.16 AKT1 BRAF GNAS MAP2K2 NFE2L2 PIK3CA
8 integument MP:0010771 10.14 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2
9 neoplasm MP:0002006 10.13 AKT1 BRAF FGFR3 GNAS HRAS IDH2
10 craniofacial MP:0005382 10.11 BRAF FGFR3 GNAS HRAS MAP2K2 NFE2L2
11 digestive/alimentary MP:0005381 10.1 BRAF FGFR3 HRAS MAP2K2 NFE2L2 PTEN
12 normal MP:0002873 9.96 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2
13 liver/biliary system MP:0005370 9.91 AKT1 BRAF GNAS NFE2L2 PTEN SMAD4
14 renal/urinary system MP:0005367 9.76 BRAF FGFR3 GNAS HRAS NFE2L2 PTEN
15 respiratory system MP:0005388 9.56 AKT1 BRAF FGFR3 GNAS HRAS NFE2L2
16 skeleton MP:0005390 9.36 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2

Drugs & Therapeutics for Squamous Cell Carcinoma, Head and Neck

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Erbitux 18 49 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
2
Ethyol 18 AMIFOSTINE Alza December 8, 1995

Drugs for Squamous Cell Carcinoma, Head and Neck (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 418)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
2
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 205923-56-4 56842117 2333
3
Petrolatum Approved, Investigational Phase 4 8009-03-8
4
Titanium dioxide Approved Phase 4 13463-67-7
5
Ethanol Approved Phase 4,Phase 1,Not Applicable 64-17-5 702
6
mometasone furoate Approved, Vet_approved Phase 4 83919-23-7
7
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 6006 143
8
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
9
Cevimeline Approved Phase 4 107233-08-9 83898 25137844
10
Raltitrexed Approved, Investigational Phase 4 112887-68-0 104758
11
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
12 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
14 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
16 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
18 Alkylating Agents Phase 4,Phase 2,Phase 1
19 Mitomycins Phase 4,Phase 2,Not Applicable
20 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
21 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Anti-Allergic Agents Phase 4,Phase 2
23 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1
24 Cholinergic Agents Phase 4,Phase 3,Early Phase 1
25 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
26 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
28 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1
29 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
30 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
31 Folate Phase 4,Phase 3,Phase 2,Phase 1
32 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Muscarinic Agonists Phase 4
34
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
35
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 15663-27-1 2767 441203 84093
36
Citalopram Approved Phase 3 59729-33-8 2771
37
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
38
Epinephrine Approved, Vet_approved Phase 3,Phase 2,Not Applicable 51-43-4 5816
39
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
40
Racepinephrine Approved Phase 3,Phase 2,Not Applicable 329-65-7 838
41
Methotrexate Approved Phase 3,Phase 2,Phase 1 59-05-2, 1959-05-2 126941
42
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
43
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 114977-28-5 148124
44
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
45
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
46
Nivolumab Approved Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 946414-94-4
47
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
48
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
49
Cobalt Approved, Experimental Phase 3,Phase 2 7440-48-4 104729
50
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379

Interventional clinical trials:

(show top 50) (show all 876)
# Name Status NCT ID Phase Drugs
1 Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
2 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
3 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4 Erbitux®
4 An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck Completed NCT00684385 Phase 4 ZD1839
5 Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed NCT00466388 Phase 4 Cevimeline
6 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
7 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC. Recruiting NCT03196843 Phase 4 Raltitrexed
8 E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
9 Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment Unknown status NCT00935675 Phase 3 Escitalopram
10 Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer. Unknown status NCT01124409 Phase 3
11 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
12 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
13 Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone Unknown status NCT00041626 Phase 3
14 Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate Unknown status NCT00041613 Phase 3
15 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
16 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
17 Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT01086826 Phase 3 RT+CDDP/5-FU;RT+CETUXIMAB;INDUCTION CTx(TPF)+(RT+CDDP/5-FU);INDUCTION CTx(TPF)+(RT+CETUXIMAB)
18 Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck Completed NCT00442455 Phase 3 Erlotinib chlorhydrate;Cisplatin
19 Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects Completed NCT01012258 Phase 3
20 Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) Completed NCT00206219 Phase 3 Gefitinib;methotrexate
21 Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Completed NCT00401323 Phase 2, Phase 3 docetaxel (XRP6976);cisplatin;5-fluorouracil (5-FU)
22 A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck Completed NCT01177956 Phase 3 Cisplatin;5-Fluorouracil
23 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
24 Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial Completed NCT00995293 Phase 3 DOCETAXEL;CISPLATIN;5-FLUOROURACIL
25 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
26 Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME) Completed NCT00122460 Phase 3 Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU);Platinum (Cisplatin or Carboplatin) + 5-FU
27 DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC Completed NCT00496652 Phase 3 Zalutumumab
28 Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer Completed NCT00460265 Phase 3 ARM 2;ARM 1
29 Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers Completed NCT01166542 Phase 3 Carboplatin;Paclitaxel;Placebo
30 LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy Completed NCT01345682 Phase 3 Afatinib;Methotrexate
31 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
32 TRACE: Tirapazamine-Radiation And Cisplatin Evaluation Completed NCT00174837 Phase 3 Tirapazamine;Cisplatin
33 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin
34 Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00054561 Phase 3 isotretinoin
35 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
36 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3 chemotherapy;cisplatin
37 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
38 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3 Biafine cream
39 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3 cisplatin;docetaxel;fluorouracil
40 Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery Completed NCT00424255 Phase 3 Lapatinib
41 Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer Completed NCT00273546 Phase 3 XRP6976 (Docetaxel/Taxotere)
42 Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT Completed NCT01931150 Phase 3 Topical Dapsone 5% Gel;oral antibiotics
43 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
44 Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer Completed NCT03370367 Phase 3 13-cis retinoic acid
45 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
46 Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity Completed NCT01265849 Phase 3
47 NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab) Recruiting NCT01950689 Phase 3 Nimorazole
48 Changes in Body Composition After EPA Supplementation in Head and Neck Patients Recruiting NCT02715596 Phase 3
49 Randomized Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma Recruiting NCT03519048 Phase 3
50 A Study of Atezolizumab (Anti−Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck Recruiting NCT03452137 Phase 3 Atezolizumab;Placebo

Search NIH Clinical Center for Squamous Cell Carcinoma, Head and Neck

Cochrane evidence based reviews: carcinoma, squamous cell of head and neck

Genetic Tests for Squamous Cell Carcinoma, Head and Neck

Genetic tests related to Squamous Cell Carcinoma, Head and Neck:

# Genetic test Affiliating Genes
1 Squamous Cell Carcinoma of the Head and Neck 29 ING1 TNFRSF10B

Anatomical Context for Squamous Cell Carcinoma, Head and Neck

MalaCards organs/tissues related to Squamous Cell Carcinoma, Head and Neck:

41
Skin, Lung, Lymph Node, Salivary Gland, T Cells, Testes, Liver

Publications for Squamous Cell Carcinoma, Head and Neck

Articles related to Squamous Cell Carcinoma, Head and Neck:

(show top 50) (show all 1176)
# Title Authors Year
1
High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy. ( 29345108 )
2018
2
Immunocompromised patients with metastatic cutaneous nodal squamous cell carcinoma of the head and neck: Poor outcome unrelated to the index lesion. ( 29360262 )
2018
3
Meta-analysis of clinical trials comparing the efficacy and safety of liposomal cisplatin versus conventional nonliposomal cisplatin in nonsmall cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN). ( 30431590 )
2018
4
Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck. ( 30511880 )
2018
5
Salvage Surgery for Recurrence after Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. ( 30526317 )
2018
6
Use of 18F-FDG PET/CT Imaging for Radiotherapy Target Volume Delineation after Induction Chemotherapy and for Prognosis of Locally Advanced Squamous Cell Carcinoma of the Head and Neck. ( 30544718 )
2018
7
Pattern of planned systemic therapy usage in newly diagnosed, nonmetastatic squamous cell carcinoma of the head and neck in a commercially insured population in the United States. ( 30421818 )
2018
8
Real-world treatment patterns and outcomes of patients with stage IV squamous cell carcinoma of the head and neck. ( 30426780 )
2018
9
Natural history of untreated squamous cell carcinoma of the head and neck. ( 30444304 )
2018
10
Multivariate analysis of potential risk factors for lymph node metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. ( 30447320 )
2018
11
Associations Between Poor Oral Health and Risk of Squamous Cell Carcinoma of the Head and Neck: A Meta-Analysis of Observational Studies. ( 30448433 )
2018
12
Window Studies in Squamous Cell Carcinoma of the Head and Neck: Values and Limits. ( 30367283 )
2018
13
Multivariate analysis of potential risk factors for lymph node metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. ( 30389358 )
2018
14
Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database. ( 30409293 )
2018
15
Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines? ( 30289965 )
2018
16
"Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach." ( 30307465 )
2018
17
LncRNA PVT1 promotes malignant progression in squamous cell carcinoma of the head and neck. ( 30310517 )
2018
18
Patritumab with Cetuximab Plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase-Ib Study. ( 30327312 )
2018
19
Treatment outcomes of unknown primary squamous cell carcinoma of the head and neck. ( 30335795 )
2018
20
Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck. ( 30198439 )
2018
21
Recurrence rates of cutaneous squamous cell carcinoma of the head and neck after Mohs micrographic surgery vs. standard excision: a retrospective cohort study. ( 30199574 )
2018
22
Corrigendum to "The role of protein methyltransferases as potential novel therapeutic targets in squamous cell carcinoma of the head and neck" [Oral Oncol. 81 (2018) 100-108]. ( 30201513 )
2018
23
Outdoor work as a risk factor for high-grade cutaneous squamous cell carcinoma of the head and neck. ( 30206456 )
2018
24
Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck. ( 30211118 )
2018
25
Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. ( 30239887 )
2018
26
Effect of ESA as a modifier of radiotherapy in curative intended treatment of squamous cell carcinoma of the head and neck (HNSCC). ( 30249347 )
2018
27
pN status predicts outcomes in surgically treated pT1-pT2 patients of various disease stages with squamous cell carcinoma of the head and neck: a 17-year retrospective single center cohort study. ( 30159726 )
2018
28
Tumor-associated macrophages derived CCL18 promotes metastasis in squamous cell carcinoma of the head and neck. ( 30181713 )
2018
29
Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: A hospital-based retrospective evidence. ( 30112336 )
2018
30
Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck. ( 30115475 )
2018
31
Local recurrence of squamous cell carcinoma of the head and neck after radio(chemo)therapy: Diagnostic performance of FDG-PET/MRI with diffusion-weighted sequences. ( 28812148 )
2018
32
Predictive value of the 8th edition American Joint Commission Cancer (AJCC) nodal staging system for patients with cutaneous squamous cell carcinoma of the head and neck. ( 29049841 )
2018
33
Prognostic factors for parotid metastasis of cutaneous squamous cell carcinoma of the head and neck. ( 29100720 )
2018
34
Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. ( 29126314 )
2018
35
Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin. ( 29180609 )
2018
36
Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). ( 29235112 )
2018
37
Comparison of Tumor Classifications for Cutaneous Squamous Cell Carcinoma of the Head and Neck in the 7th vs 8th Edition of the AJCC Cancer Staging Manual. ( 29261835 )
2018
38
Re-irradiation with curative intent in patients with squamous cell carcinoma of the head and neck: a national survey of usual practice on behalf of the Italian Association of Radiation Oncology (AIRO). ( 29279949 )
2018
39
KDM5B overexpression predicts a poor prognosis in patients with squamous cell carcinoma of the head and neck. ( 29290786 )
2018
40
Unknown primary squamous cell carcinoma of the head and neck: retrospective analysis of 80 cases. ( 29310489 )
2018
41
Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in 18F-FDG PET in Squamous Cell Carcinoma of the Head and Neck. ( 29311707 )
2018
42
Dynamic changes in 18F-borono-L-phenylalanine uptake in unresectable, advanced, or recurrent squamous cell carcinoma of the head and neck and malignant melanoma during boron neutron capture therapy patient selection. ( 29325590 )
2018
43
Telomeric Repeat-Containing RNAs (TERRA) Decrease in Squamous Cell Carcinoma of the Head and Neck Is Associated with Worsened Clinical Outcome. ( 29342094 )
2018
44
Searching for New Targets and Treatments in the Battle Against Squamous Cell Carcinoma of the Head and Neck, with Specific Focus on Tumours of the Tongue. ( 29345578 )
2018
45
Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN). ( 29346507 )
2018
46
Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neck. ( 29346519 )
2018
47
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). ( 29408977 )
2018
48
Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. ( 29452770 )
2018
49
Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1. ( 29490986 )
2018
50
DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group. ( 29523409 )
2018

Variations for Squamous Cell Carcinoma, Head and Neck

UniProtKB/Swiss-Prot genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

75
# Symbol AA change Variation ID SNP ID
1 ING1 p.Ala335Asp VAR_017420
2 ING1 p.Cys358Ser VAR_017421
3 ING1 p.Asn359Ser VAR_017422
4 ING3 p.Asp20Gly VAR_021263
5 PTEN p.Ala121Gly VAR_018103 rs121909237

ClinVar genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

6 (show top 50) (show all 693)
# Gene Variation Type Significance SNP ID Assembly Location
1 TNFRSF10B TNFRSF10B, 2-BP INS insertion Pathogenic
2 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
3 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
4 PTEN NM_000314.6(PTEN): c.362C> G (p.Ala121Gly) single nucleotide variant Pathogenic rs121909237 GRCh37 Chromosome 10, 89692878: 89692878
5 PTEN NM_000314.6(PTEN): c.362C> G (p.Ala121Gly) single nucleotide variant Pathogenic rs121909237 GRCh38 Chromosome 10, 87933121: 87933121
6 ING1 NM_198217.2(ING1): c.512G> C (p.Cys171Ser) single nucleotide variant Pathogenic rs121909250 GRCh37 Chromosome 13, 111372083: 111372083
7 ING1 NM_198217.2(ING1): c.512G> C (p.Cys171Ser) single nucleotide variant Pathogenic rs121909250 GRCh38 Chromosome 13, 110719736: 110719736
8 ING1 NM_198217.2(ING1): c.515A> G (p.Asn172Ser) single nucleotide variant Pathogenic rs121909251 GRCh37 Chromosome 13, 111372086: 111372086
9 ING1 NM_198217.2(ING1): c.515A> G (p.Asn172Ser) single nucleotide variant Pathogenic rs121909251 GRCh38 Chromosome 13, 110719739: 110719739
10 ING1 NM_198217.2(ING1): c.443C> A (p.Ala148Asp) single nucleotide variant Pathogenic rs121909252 GRCh37 Chromosome 13, 111372014: 111372014
11 ING1 NM_198217.2(ING1): c.443C> A (p.Ala148Asp) single nucleotide variant Pathogenic rs121909252 GRCh38 Chromosome 13, 110719667: 110719667
12 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 GRCh37 Chromosome 19, 4117551: 4117551
13 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 GRCh38 Chromosome 19, 4117553: 4117553
14 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
15 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh38 Chromosome 18, 51065548: 51065548
16 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
17 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
18 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
19 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
20 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
21 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
22 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
23 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
24 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
25 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
26 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
27 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
28 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
29 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
30 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
31 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
32 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
33 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
34 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
35 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
36 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
37 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
38 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
39 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
40 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
41 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
42 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
43 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
44 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
45 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
46 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
47 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
48 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
49 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
50 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289

Cosmic variations for Squamous Cell Carcinoma, Head and Neck:

9 (show top 50) (show all 4118)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10662 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 88
2 COSM607136 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1247C>T p.S416F 9:99146601-99146601 88
3 COSM6962965 SMO skin,neck,carcinoma,squamous cell carcinoma c.1103C>T p.P368L 7:129206332-129206332 88
4 COSM6962990 RARA skin,neck,carcinoma,squamous cell carcinoma c.1384C>T p.P462S 17:40356221-40356221 88
5 COSM6962984 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 88
6 COSM6962994 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 88
7 COSM6962992 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 88
8 COSM6962970 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1736G>A p.S579N 9:8504347-8504347 88
9 COSM456125 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.5048C>T p.S1683F 9:8341168-8341168 88
10 COSM1700914 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1261C>T p.P421S 9:8518130-8518130 88
11 COSM6962989 PLCG2 skin,neck,carcinoma,squamous cell carcinoma c.115G>T p.E39* 16:81786104-81786104 88
12 COSM6962963 PIK3CG skin,neck,carcinoma,squamous cell carcinoma c.310G>A p.G104R 7:106867871-106867871 88
13 COSM6962964 PIK3CG skin,neck,carcinoma,squamous cell carcinoma c.3227G>A p.R1076K 7:106905305-106905305 88
14 COSM564 NRAS skin,neck,carcinoma,squamous cell carcinoma c.35G>A p.G12D 1:114716126-114716126 88
15 COSM6962996 NCOA3 skin,neck,carcinoma,squamous cell carcinoma c.979C>T p.H327Y 20:47634062-47634062 88
16 COSM4170532 MTOR skin,neck,carcinoma,squamous cell carcinoma c.3409G>A p.E1137K 1:11212464-11212464 88
17 COSM6962967 KMT2C skin,neck,carcinoma,squamous cell carcinoma c.11659C>T p.H3887Y 7:152158874-152158874 88
18 COSM6962983 KMT2A skin,neck,carcinoma,squamous cell carcinoma c.4377T>G p.C1459W 11:118488658-118488658 88
19 COSM498 HRAS skin,neck,carcinoma,squamous cell carcinoma c.182A>T p.Q61L 11:533874-533874 88
20 COSM6438927 HGF skin,neck,carcinoma,squamous cell carcinoma c.974C>T p.P325L 7:81729671-81729671 88
21 COSM6962960 FGFR3 skin,neck,carcinoma,squamous cell carcinoma c.2421A>G p.*807W 4:1807262-1807262 88
22 COSM6962980 FGFR2 skin,neck,carcinoma,squamous cell carcinoma c.2234C>T p.S745F 10:121483765-121483765 88
23 COSM6962962 EPHA7 skin,neck,carcinoma,squamous cell carcinoma c.2468G>A p.G823E 6:93254711-93254711 88
24 COSM5918388 EPHA5 skin,neck,carcinoma,squamous cell carcinoma c.2608G>A p.E870K 4:65348104-65348104 88
25 COSM6962957 EPHA3 skin,neck,carcinoma,squamous cell carcinoma c.632T>A p.M211K 3:89210338-89210338 88
26 COSM6946976 EPHA3 skin,neck,carcinoma,squamous cell carcinoma c.533G>A p.G178E 3:89210239-89210239 88
27 COSM6962956 CASP8 skin,neck,carcinoma,squamous cell carcinoma c.1382C>T p.T461I 2:201286485-201286485 88
28 COSM3713589 CASP8 skin,neck,carcinoma,squamous cell carcinoma c.1093C>T p.L365F 2:201285055-201285055 88
29 COSM21323 ATM skin,neck,carcinoma,squamous cell carcinoma c.1009C>T p.R337C 11:108247071-108247071 88
30 COSM6950941 APC skin,neck,carcinoma,squamous cell carcinoma c.536C>T p.S179F 5:112780794-112780794 88
31 COSM6962953 AKT3 skin,neck,carcinoma,squamous cell carcinoma c.1164-1G>A p.? 1:243545598-243545598 88
32 COSM6962993 skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 88
33 COSM1640830 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 88
34 COSM6962974 skin,neck,carcinoma,squamous cell carcinoma c.1231C>T p.P411S 9:8518130-8518130 88
35 COSM6962968 skin,neck,carcinoma,squamous cell carcinoma c.1736G>A p.S579N 9:8504347-8504347 88
36 COSM6962949 skin,neck,carcinoma,squamous cell carcinoma c.493C>T p.P165S 1:77966737-77966737 88
37 COSM6962972 skin,neck,carcinoma,squamous cell carcinoma c.1727G>A p.S576N 9:8504347-8504347 88
38 COSM6962978 skin,neck,carcinoma,squamous cell carcinoma c.2237C>T p.S746F 10:121483765-121483765 88
39 COSM6962995 skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 88
40 COSM1350749 skin,neck,carcinoma,squamous cell carcinoma c.1009C>T p.R337C 11:108247071-108247071 88
41 COSM6962951 skin,neck,carcinoma,squamous cell carcinoma c.1164-1G>A p.? 1:243545598-243545598 88
42 COSM1700913 skin,neck,carcinoma,squamous cell carcinoma c.1261C>T p.P421S 9:8518130-8518130 88
43 COSM1700915 skin,neck,carcinoma,squamous cell carcinoma c.1252C>T p.P418S 9:8518130-8518130 88
44 COSM6962982 skin,neck,carcinoma,squamous cell carcinoma c.4377T>G p.C1459W 11:118488658-118488658 88
45 COSM6962950 skin,neck,carcinoma,squamous cell carcinoma c.430C>T p.P144S 1:77966737-77966737 88
46 COSM1700912 skin,neck,carcinoma,squamous cell carcinoma c.1261C>T p.P421S 9:8518130-8518130 88
47 COSM6962991 skin,neck,carcinoma,squamous cell carcinoma c.1369C>T p.P457S 17:40356221-40356221 88
48 COSM99020 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 88
49 COSM6962979 skin,neck,carcinoma,squamous cell carcinoma c.1967C>T p.S656F 10:121483765-121483765 88
50 COSM99021 skin,neck,carcinoma,squamous cell carcinoma c.464G>A p.R155Q 17:7674220-7674220 88

Copy number variations for Squamous Cell Carcinoma, Head and Neck from CNVD:

7 (show all 42)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 33952 1 50700000 61300000 Amplification head and neck squamous cell carcinoma
2 71135 12 67700000 71500000 Amplification head and neck squamous cell carcinoma
3 78639 13 55300000 73300000 Amplification head and neck squamous cell carcinoma
4 90904 15 25700000 28100000 Amplification head and neck squamous cell carcinoma
5 93784 15 59100000 59300000 Copy number MET head and neck squamous cell carcinoma
6 118006 17 7505821 7531588 LOH TP53 head and neck squamous cell carcinoma
7 119192 18 1 7100000 Amplification head and neck squamous cell carcinoma
8 119790 18 17200000 19000000 Amplification head and neck squamous cell carcinoma
9 166134 3 1 87900000 Loss head and neck squamous cell carcinoma
10 167635 3 121900000 167600000 Gain head and neck squamous cell carcinoma
11 169556 3 142800000 148900000 Amplification head and neck squamous cell carcinoma
12 171486 3 168801287 168851758 Amplification EVI1 head and neck squamous cell carcinoma
13 171495 3 168867391 169381563 Amplification MDS1 head and neck squamous cell carcinoma
14 172487 3 182700000 187900000 Amplification RFC4 head and neck squamous cell carcinoma
15 174746 12 7773277 7793336 Deletion DLEC head and neck squamous cell carcinoma
16 179443 3 91000000 121900000 Gain head and neck squamous cell carcinoma
17 179973 4 1 50400000 Loss head and neck squamous cell carcinoma
18 204736 6 114600000 171115067 Gain head and neck squamous cell carcinoma
19 217049 7 1 159138663 Copy number head and neck squamous cell carcinoma
20 225369 7 45400000 54000000 Gain EGFR head and neck squamous cell carcinoma
21 225383 7 45400000 54000000 Amplification EGFR head and neck squamous cell carcinoma
22 225403 7 45400000 54000000 Copy number EGFR head and neck squamous cell carcinoma
23 225404 7 45400000 54000000 Copy number EGFR head and neck squamous cell carcinoma
24 225408 7 45400000 54000000 Deletion or amplific ation EGFR head and neck squamous cell carcinoma
25 225413 7 45400000 58000000 Amplification head and neck squamous cell carcinoma
26 226532 7 58000000 59900000 Amplification head and neck squamous cell carcinoma
27 232747 8 119200000 122500000 Gain MYC head and neck squamous cell carcinoma
28 233769 8 127300000 139900000 Gain KHDRBS3 head and neck squamous cell carcinoma
29 234876 8 139900000 146364022 Gain FAK head and neck squamous cell carcinoma
30 234895 8 139900000 146364022 Gain PTP4A3 head and neck squamous cell carcinoma
31 238011 8 28800000 45600000 Amplification head and neck squamous cell carcinoma
32 239988 8 43100000 45600000 Amplification head and neck squamous cell carcinoma
33 240109 8 45600000 146364022 Gain GAA1 head and neck squamous cell carcinoma
34 241899 8 68000000 70500000 Amplification head and neck squamous cell carcinoma
35 243677 8 86900000 101600000 Amplification RUNX1T1 head and neck squamous cell carcinoma
36 249984 9 19900000 25500000 Deletion CDKN2A head and neck squamous cell carcinoma
37 300518 11 95351087 95715992 Methylation MAML2 head and neck squamous cell carcinoma
38 300530 12 123374913 123617963 Methylation NCOR2 head and neck squamous cell carcinoma
39 300892 14 72672931 72756862 Methylation PSEN1 head and neck squamous cell carcinoma
40 300893 14 72811670 72995039 Methylation NUMB head and neck squamous cell carcinoma
41 302931 19 45863651 45888396 Methylation NUMBL head and neck squamous cell carcinoma
42 303261 20 10566331 10602694 Methylation JAG1 head and neck squamous cell carcinoma

Expression for Squamous Cell Carcinoma, Head and Neck

LifeMap Discovery
Genes differentially expressed in tissues of Squamous Cell Carcinoma, Head and Neck patients vs. healthy controls: 35 (show all 15)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 MMP1 matrix metallopeptidase 1 Head Mesenchyme + 5.25 0.000
2 TMPRSS11B transmembrane protease, serine 11B Head Mesenchyme - 4.81 0.000
3 CRISP3 cysteine-rich secretory protein 3 Head Mesenchyme - 4.48 0.000
4 MAL mal, T-cell differentiation protein Head Mesenchyme - 4.39 0.000
5 INHBA inhibin, beta A Head Mesenchyme + 4.13 0.000
6 CRNN cornulin Head Mesenchyme - 4.00 0.000
7 KRT17 keratin 17, type I Head Mesenchyme + 3.94 0.000
8 KRT4 keratin 4, type II Head Mesenchyme - 3.41 0.000
9 PTHLH parathyroid hormone-like hormone Head Mesenchyme + 3.36 0.000
10 CTHRC1 collagen triple helix repeat containing 1 Head Mesenchyme + 3.32 0.000
11 CLCA4 chloride channel accessory 4 Head Mesenchyme - 3.31 0.000
12 WDR72 WD repeat domain 72 Head Mesenchyme + 3.23 0.000
13 MMP10 matrix metallopeptidase 10 Head Mesenchyme + 3.14 0.001
14 TGM3 transglutaminase 3 Head Mesenchyme - 3.08 0.000
15 GBP1 guanylate binding protein 1, interferon-inducible Head Mesenchyme + 3.06 0.000
Search GEO for disease gene expression data for Squamous Cell Carcinoma, Head and Neck.

Pathways for Squamous Cell Carcinoma, Head and Neck

Pathways related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show top 50) (show all 149)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2
2
Show member pathways
13.79 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2
3
Show member pathways
13.67 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2
4
Show member pathways
13.5 AKT1 FGFR3 GNAS HRAS PTEN TNFRSF10B
5
Show member pathways
13.5 AKT1 BRAF GNAS HRAS MAP2K2 PIK3CA
6
Show member pathways
13.46 AKT1 BRAF FGFR3 HRAS MAP2K2 PIK3CA
7
Show member pathways
13.32 AKT1 BRAF GNAS HRAS MAP2K2 PTEN
8
Show member pathways
13.21 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2
9
Show member pathways
13.19 AKT1 GNAS HRAS MAP2K2 PIK3CA PTEN
10
Show member pathways
13.12 AKT1 BRAF GNAS HRAS MAP2K2 TP53
11
Show member pathways
13.12 AKT1 FGFR3 GNAS HRAS MAP2K2 PIK3CA
12
Show member pathways
13.08 AKT1 HRAS MAP2K2 PIK3CA PTEN TNFRSF10B
13
Show member pathways
13.06 AKT1 BRAF GNAS HRAS MAP2K2 PIK3CA
14
Show member pathways
13.02 AKT1 BRAF HRAS MAP2K2 PIK3CA PTEN
15
Show member pathways
13.02 AKT1 BRAF HRAS MAP2K2 PIK3CA PTEN
16
Show member pathways
12.99 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2
17
Show member pathways
12.99 AKT1 BRAF HRAS MAP2K2 PIK3CA PTEN
18
Show member pathways
12.94 AKT1 HRAS MAP2K2 PIK3CA TNFRSF10B TP53
19
Show member pathways
12.91 AKT1 BRAF HRAS MAP2K2 PIK3CA PTEN
20
Show member pathways
12.9 AKT1 BRAF GNAS HRAS MAP2K2
21
Show member pathways
12.89 AKT1 MAP2K2 PIK3CA TNFRSF10B TP53
22 12.89 AKT1 BRAF FGFR3 HRAS MAP2K2 TP53
23
Show member pathways
12.86 AKT1 FGFR3 HRAS PIK3CA PTEN TP53
24
Show member pathways
12.86 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2
25
Show member pathways
12.84 AKT1 BRAF HRAS MAP2K2 PIK3CA PTEN
26
Show member pathways
12.83 AKT1 BRAF GNAS HRAS MAP2K2
27
Show member pathways
12.79 AKT1 BRAF HRAS MAP2K2 TP53
28
Show member pathways
12.79 AKT1 GNAS HRAS MAP2K2 PIK3CA PTEN
29
Show member pathways
12.78 AKT1 BRAF GNAS HRAS MAP2K2
30
Show member pathways
12.78 AKT1 BRAF FGFR3 GNAS HRAS MAP2K2
31 12.75 BRAF FGFR3 HRAS MAP2K2 PIK3CA
32
Show member pathways
12.73 AKT1 HRAS MAP2K2 PIK3CA TNFRSF10B
33
Show member pathways
12.72 AKT1 BRAF HRAS MAP2K2 NFE2L2 PIK3CA
34
Show member pathways
12.71 AKT1 HRAS MAP2K2 PIK3CA PTEN
35
Show member pathways
12.69 AKT1 GNAS HRAS MAP2K2 PIK3CA
36
Show member pathways
12.66 AKT1 BRAF HRAS MAP2K2 PIK3CA SMAD4
37
Show member pathways
12.65 AKT1 HRAS MAP2K2 PIK3CA PTEN
38
Show member pathways
12.64 BRAF HRAS MAP2K2 PIK3CA TNFRSF10B
39
Show member pathways
12.63 AKT1 BRAF HRAS MAP2K2 PIK3CA TP53
40
Show member pathways
12.61 AKT1 HRAS MAP2K2 PIK3CA PTEN
41
Show member pathways
12.59 AKT1 FGFR3 HRAS MAP2K2 PIK3CA TP53
42
Show member pathways
12.57 AKT1 FGFR3 HRAS MAP2K2 PIK3CA
43 12.56 AKT1 HRAS PIK3CA SMAD4 TP53
44
Show member pathways
12.54 AKT1 GNAS HRAS MAP2K2 PIK3CA
45
Show member pathways
12.53 AKT1 BRAF HRAS MAP2K2 PIK3CA
46
Show member pathways
12.53 AKT1 HRAS MAP2K2 PIK3CA PTEN TP53
47
Show member pathways
12.52 AKT1 HRAS PIK3CA TP53
48
Show member pathways
12.52 AKT1 HRAS MAP2K2 PIK3CA
49
Show member pathways
12.52 BRAF GNAS HRAS MAP2K2
50
Show member pathways
12.52 AKT1 BRAF HRAS MAP2K2 PIK3CA PTEN

GO Terms for Squamous Cell Carcinoma, Head and Neck

Cellular components related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.02 H19 MIR205 MIR21 MIR210 MIR98

Biological processes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.95 AKT1 ING1 MAP2K2 NFE2L2 SMAD4 TP53
2 negative regulation of gene expression GO:0010629 9.92 AKT1 HRAS MAP2K2 MIR21
3 cell proliferation GO:0008283 9.91 AKT1 HRAS PTEN SMAD4 TP53
4 negative regulation of apoptotic process GO:0043066 9.91 AKT1 BRAF FGFR3 MIR21 PTEN TP53
5 MAPK cascade GO:0000165 9.88 BRAF FGFR3 HRAS MAP2K2
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.79 AKT1 BRAF PIK3CA
7 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.77 MIR21 PTEN SMAD4
8 cellular response to drug GO:0035690 9.73 BRAF NFE2L2 TP53
9 positive regulation of blood vessel endothelial cell migration GO:0043536 9.67 AKT1 MIR210 NFE2L2
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.65 BRAF FGFR3 HRAS MIR21 PTEN
11 negative regulation of macroautophagy GO:0016242 9.63 AKT1 PIK3CA
12 negative regulation of cell proliferation GO:0008285 9.63 HRAS ING1 MIR21 PTEN SMAD4 TP53
13 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.62 AKT1 NFE2L2
14 cellular response to hypoxia GO:0071456 9.62 AKT1 NFE2L2 PTEN TP53
15 anoikis GO:0043276 9.61 AKT1 PIK3CA
16 negative regulation of cell size GO:0045792 9.6 AKT1 PTEN
17 positive regulation of metalloendopeptidase activity GO:1904685 9.58 MIR205 MIR21
18 protein kinase B signaling GO:0043491 9.58 AKT1 PIK3CA PTEN
19 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.57 MAP2K2 TP53
20 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.55 MIR21 MIR210
21 regulation of axon regeneration GO:0048679 9.54 BRAF PTEN
22 cellular response to nerve growth factor stimulus GO:1990090 9.54 AKT1 BRAF PTEN
23 cellular response to decreased oxygen levels GO:0036294 9.46 AKT1 PTEN
24 positive regulation of apoptotic process GO:0043065 9.43 AKT1 ING3 MIR21 PTEN TNFRSF10B TP53
25 positive regulation of gene expression GO:0010628 9.17 AKT1 BRAF HRAS MIR21 NFE2L2 PTEN
26 positive regulation of cell proliferation GO:0008284 10.03 AKT1 FGFR3 HRAS MIR21 PTEN
27 apoptotic process GO:0006915 10 AKT1 FGFR3 HRAS PTEN TNFRSF10B TP53

Molecular functions related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.02 AKT1 BRAF FGFR3 HRAS MAP2K2

Sources for Squamous Cell Carcinoma, Head and Neck

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....